• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SERTRALINE Drug Record

  • Summary
  • Interactions
  • Claims
  • SERTRALINE chembl:CHEMBL809 Approved

    Alternate Names:

    SERTRALINE
    ZOLOFT®
    CP-519741
    SERTRALINE HYDROCHLORIDE
    (+)-SERTRALINE
    CP 51974
    CP-51974-1
    (1S,4S)-SERTRALINE
    (1S-CIS)-1,2,3,4-TETRAHYDRO-4-(3,4-DICHLOROPHENYL)-N-METHYL-1-NAPHTHALENAMINE
    CIS-(+)-SERTRALINE
    LUSTRAL®
    SERTRALINA
    SERTRALINUM
    ZOLOFT
    chembl:CHEMBL809
    drugbank:01104
    rxcui:36437
    chemidplus:79617-96-2
    pubchem.compound:68617

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidepressant,for treatment of obsessive compulsive disorder (OCD)
    Year of Approval 1991
    Drug Class antidepressive agents
    (2 More Sources)

    Publications:

    Firouzabadi D et al., 2019, Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder., Eur J Clin Pharmacol
    Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
    Benmansour et al., 2002, Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter., J. Neurosci.
    Benmansour et al., 1999, Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level., J. Neurosci.
    Iehlé et al., 1993, Baculovirus-directed expression of human prostatic steroid 5 alpha-reductase 1 in an active form., J. Steroid Biochem. Mol. Biol.
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Chen et al., 2005, Characterization of an allosteric citalopram-binding site at the serotonin transporter., J. Neurochem.
    Borkowska et al., [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]., Psychiatr. Pol.
    Durham et al., 2004, The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder., Psychopharmacology (Berl.)
    David et al., 2001, Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice., Psychopharmacology (Berl.)
    Muneoka et al., 2009, Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats., Neurochem. Res.
    Rogóz et al., Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats., Pharmacol Rep
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Ishiguro S et al., 2011, Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder., Eur J Clin Pharmacol
    Yevtushenko OO et al., 2010, Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism., J Affect Disord
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Kato M et al., 2009, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
    Baune BT et al., 2008, Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?, Neurosci Lett
    Drago A et al., 2008, 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies., Int J Neuropsychopharmacol
    Bahramali E et al., 2016, Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial., Eur J Clin Pharmacol
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Lemke, 2007, [Antidepressant effects of dopamine agonists. Experimental and clinical findings]., Nervenarzt
    Nemeroff et al., 2004, Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis., CNS Spectr
    Ghanizadeh, 2008, Sertraline-associated hair loss., J Drugs Dermatol
    Goodnick et al., 1998, Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology., J. Psychopharmacol. (Oxford)
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
    Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
    de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
    Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
    Yuce-Artun N et al., 2016, Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients., Int J Clin Pharm
  • SERTRALINE   P3H3

    Interaction Score: 5.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30324302


    Sources:
    PharmGKB

  • SERTRALINE   SRP19

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • SERTRALINE   REEP5

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • SERTRALINE   CFL1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • SERTRALINE   SLC6A4

    Interaction Score: 0.68

    Interaction Types & Directionality:
    negative modulator (inhibitory)
    binder
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Zoloft
    Novel drug target Established target

    PMIDs:
    12151556 10575045 8664165 9537821 15606893 12647451 12955294 11243491 18751896 16963794


    Sources:
    TdgClinicalTrial TEND

  • SERTRALINE   GNB3

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30324302


    Sources:
    PharmGKB

  • SERTRALINE   HTR1A

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 21688171 19800133 19590397 18484082 18387740 18047755


    Sources:
    PharmGKB

  • SERTRALINE   SLC6A3

    Interaction Score: 0.35

    Interaction Types & Directionality:
    binder
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Zoloft
    Novel drug target Established target

    PMIDs:
    17187269 15181382 18664165 9537821 9808077


    Sources:
    TdgClinicalTrial

  • SERTRALINE   HLA-A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SERTRALINE   JUN

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • SERTRALINE   CYP2B6

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26830411


    Sources:
    PharmGKB

  • SERTRALINE   CDK1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • SERTRALINE   ACE

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27262302


    Sources:
    PharmGKB

  • SERTRALINE   COMT

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SERTRALINE   ABCB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26704739 24192121 22641028 18215618


    Sources:
    PharmGKB

  • SERTRALINE   CYP3A5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SERTRALINE   DRD1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SERTRALINE   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • SERTRALINE   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SERTRALINE   IDH1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SERTRALINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • TEND: SERTRALINE

    • Version: 01-August-2011

    Alternate Names:
    SERTRALINE Primary Drug Name

    Drug Info:
    Drug Class antidepressive agents
    Year of Approval 1991

    Publications:

  • TdgClinicalTrial: SERTRALINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant,for treatment of obsessive compulsive disorder (OCD)
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: SERTRALINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL809 ChEMBL Drug ID

    Drug Info:

    Publications:
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

  • PharmGKB: sertraline

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
    Firouzabadi D et al., 2019, Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder., Eur J Clin Pharmacol
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport

  • TTD: Sertraline

    • Version: 2020.06.01

    Alternate Names:
    D0K0TC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL809

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21